Application of Lobaplatin in Trans-catheter Arterial Chemoembolization for Primary Hepatic Carcinoma
Application of Lobaplatin in Trans-catheter Arterial Chemoembolization for Primary Hepatic Carcinoma
复制标题
DOI：
10.7314/apjcp.2014.15.2.647
复制
发表时间：
2014-01-01
影响因子：
--
通讯作者：
Li, Jia-Rui
中科院分区：
文献类型：
--
作者：
Wang, Nan;Lv, Yin-Zhang;Li, Jia-Rui
目的：探讨洛铂在经皮肝动脉化疗栓塞术(TACE)治疗不能或不愿手术的原发性肝癌中的疗效。方法：将173例经影像或病理证实的原发性肝癌患者随机分为实验组和对照组，分别用洛铂和吡柔比星作为化疗药物进行TACE治疗。根据肿瘤个数和大小调整碘平量，然后用明胶海绵或聚乙烯醇颗粒进行栓塞术。比较两组患者的生存时间和治疗反应。结果：试验组(单用洛铂为化疗药物)在生存时间和疗效方面均优于对照组(单用盐酸吡柔比星为化疗药物)，有统计学意义。结论：单用洛铂可作为TACE的化疗药物，在平均生存时间和疗效方面有较好的疗效，值得临床推广。
Objective: To explore the efficiency of single application of lobaplatin in tran-scatheter arterial chemoembolization (TACE) for patients with a primary hepatic carcinoma who were unable or unwilling to undergo surgery. Methods: 173 patients with primary hepatic carcinoma diagnosed by imaging or pathology were randomly divided into experimental and control groups and respectively treated with lobaplatin and pirarubicin hydrochloride as chemotherapeutic drugs for TACE. The amount of iodipin was regulated according to the tumor number and size, and then gelatin sponge or polyvinyl alcohol particles were applied for embolisms. The efficiency of treatment in the two groups was compared with reference to survival time and therapeutic response. Results: The experimental group (single lobaplatin as chemotherapy drug) was superior to control group (single pirarubicin hydrochloride as chemotherapy drug) in the aspects of survival time and therapeutic response, with statistical significance. Conclusions: Single lobaplatin can be as a chemotherapy drug in TACE and has better efficiency in the aspects of mean survival time and therapeutic response, deserving to be popularized in the clinic.